189 related articles for article (PubMed ID: 25574915)
41. [The cost of treatment in new case and multidrug resistant case in pulmonary tuberculosis].
Kizkin O; Hacievliyagil SS; Türker G; Günen H
Tuberk Toraks; 2003; 51(4):410-5. PubMed ID: 15143390
[TBL] [Abstract][Full Text] [Related]
42. The Impact and Cost-Effectiveness of a Four-Month Regimen for First-Line Treatment of Active Tuberculosis in South Africa.
Knight GM; Gomez GB; Dodd PJ; Dowdy D; Zwerling A; Wells WA; Cobelens F; Vassall A; White RG
PLoS One; 2015; 10(12):e0145796. PubMed ID: 26717007
[TBL] [Abstract][Full Text] [Related]
43. Economic burden of multidrug-resistant tuberculosis: a multicenter study across Vietnamese regions.
Nam VX; Nhung NV; Hoa NB; Thuy HTT; Phuong NTM; Anh NT; Anh LTN; Trung VQ; Ha TV; Meeyai A; Thavorncharoensap M; Chaikledkaew U
Int J Tuberc Lung Dis; 2018 Aug; 22(8):912-917. PubMed ID: 29991401
[TBL] [Abstract][Full Text] [Related]
44. Effectiveness, cost, and safety of four regimens recommended by WHO for RR/MDR-TB treatment: a cohort study in Eastern China.
Gu P; Lu P; Ding H; Liu Q; Ding X; Chen Y; Zhu L
Ann Med; 2024 Dec; 56(1):2344821. PubMed ID: 38697138
[TBL] [Abstract][Full Text] [Related]
45. Estimating the impact of a novel drug regimen for treatment of tuberculosis: a modeling analysis of projected patient outcomes and epidemiological considerations.
Kendall EA; Malhotra S; Cook-Scalise S; Denkinger CM; Dowdy DW
BMC Infect Dis; 2019 Sep; 19(1):794. PubMed ID: 31500572
[TBL] [Abstract][Full Text] [Related]
46. Cost-effectiveness of rapid susceptibility testing against second-line drugs for tuberculosis.
Dowdy DW; van't Hoog A; Shah M; Cobelens F
Int J Tuberc Lung Dis; 2014 Jun; 18(6):647-54. PubMed ID: 24903933
[TBL] [Abstract][Full Text] [Related]
47. Systematic review, meta-analysis and economic modelling of molecular diagnostic tests for antibiotic resistance in tuberculosis.
Drobniewski F; Cooke M; Jordan J; Casali N; Mugwagwa T; Broda A; Townsend C; Sivaramakrishnan A; Green N; Jit M; Lipman M; Lord J; White PJ; Abubakar I
Health Technol Assess; 2015 May; 19(34):1-188, vii-viii. PubMed ID: 25952553
[TBL] [Abstract][Full Text] [Related]
48. Factors affecting time to treatment initiation after diagnosis for multidrug-resistant/rifampicin-resistant tuberculosis patients: A mixed-methods study in Jakarta, Indonesia.
Silitonga P; Jiang W; Wyatt S; Burhan E; Kes EFM; Long Q
Trop Med Int Health; 2023 Jan; 28(1):43-52. PubMed ID: 36477995
[TBL] [Abstract][Full Text] [Related]
49. Cost of treatment support for multidrug-resistant tuberculosis using patient-centred approaches in Ethiopia: a model-based method.
Rosu L; Morgan L; Tomeny EM; Worthington C; Jin M; Nidoi J; Worthington D
Infect Dis Poverty; 2023 Jul; 12(1):65. PubMed ID: 37420269
[TBL] [Abstract][Full Text] [Related]
50. Travel distance to rifampicin-resistant tuberculosis treatment and its impact on loss to follow-up: the importance of continued RR-TB treatment decentralization in South Africa.
McNabb KC; Bergman AJ; Patil A; Lowensen K; Mthimkhulu N; Budhathoki C; Perrin N; Farley JE
BMC Public Health; 2024 Feb; 24(1):578. PubMed ID: 38389038
[TBL] [Abstract][Full Text] [Related]
51. Severe adverse events during second-line tuberculosis treatment in the context of high HIV Co-infection in South Africa: a retrospective cohort study.
Schnippel K; Berhanu RH; Black A; Firnhaber C; Maitisa N; Evans D; Sinanovic E
BMC Infect Dis; 2016 Oct; 16(1):593. PubMed ID: 27769174
[TBL] [Abstract][Full Text] [Related]
52. Second line drug susceptibility testing to inform the treatment of rifampin-resistant tuberculosis: a quantitative perspective.
Kendall EA; Cohen T; Mitnick CD; Dowdy DW
Int J Infect Dis; 2017 Mar; 56():185-189. PubMed ID: 28007660
[TBL] [Abstract][Full Text] [Related]
53. Cost-effectiveness of treating multidrug-resistant tuberculosis in treatment initiative centers and treatment follow-up centers in Ethiopia.
Alemayehu S; Yigezu A; Hailemariam D; Hailu A
PLoS One; 2020; 15(7):e0235820. PubMed ID: 32716915
[TBL] [Abstract][Full Text] [Related]
54. Bedaquiline- versus injectable-containing drug-resistant tuberculosis regimens: a cost-effectiveness analysis.
Ionescu AM; Mpobela Agnarson A; Kambili C; Metz L; Kfoury J; Wang S; Williams A; Singh V; Thomas A
Expert Rev Pharmacoecon Outcomes Res; 2018 Dec; 18(6):677-689. PubMed ID: 30073886
[TBL] [Abstract][Full Text] [Related]
55. Population health impact and cost-effectiveness of tuberculosis diagnosis with Xpert MTB/RIF: a dynamic simulation and economic evaluation.
Menzies NA; Cohen T; Lin HH; Murray M; Salomon JA
PLoS Med; 2012; 9(11):e1001347. PubMed ID: 23185139
[TBL] [Abstract][Full Text] [Related]
56. A systematic review of the cost and cost effectiveness of treatment for multidrug-resistant tuberculosis.
Fitzpatrick C; Floyd K
Pharmacoeconomics; 2012 Jan; 30(1):63-80. PubMed ID: 22070215
[TBL] [Abstract][Full Text] [Related]
57. Catastrophic costs of treating drug resistant TB patients in a tertiary care hospital in India.
Mullerpattan JB; Udwadia ZZ; Banka RA; Ganatra SR; Udwadia ZF
Indian J Tuberc; 2019 Jan; 66(1):87-91. PubMed ID: 30797290
[TBL] [Abstract][Full Text] [Related]
58. Multi-drug resistant tuberculosis burden and risk factors: an update.
Marahatta SB
Kathmandu Univ Med J (KUMJ); 2010; 8(29):116-25. PubMed ID: 21209520
[TBL] [Abstract][Full Text] [Related]
59. Directly observed treatment for multidrug-resistant tuberculosis: an economic evaluation in the United States of America and South Africa.
Wilton P; Smith RD; Coast J; Millar M; Karcher A
Int J Tuberc Lung Dis; 2001 Dec; 5(12):1137-42. PubMed ID: 11769772
[TBL] [Abstract][Full Text] [Related]
60. Cost of treatment for multidrug-resistant tuberculosis in South Korea.
Kang YA; Choi YJ; Cho YJ; Lee SM; Yoo CG; Kim YW; Han SK; Shim YS; Yim JJ
Respirology; 2006 Nov; 11(6):793-8. PubMed ID: 17052310
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
